#Japan #Telemedicine #Kagoshima #Gunma University #AMI Corporation

AMI Corporation Selected for Gunma's Future Co-creation Trial Subsidy

AMI Corporation, based in Kagoshima, has proudly announced its participation in the Gunma Future Co-creation Trial Subsidy for the fiscal year 7. The initiative aims to revolutionize healthcare through innovative AI medical devices and remote medical services. This selection marks a significant achievement for AMI and its consortium partners, including Gunma University and Gunma Central Hospital, which together form a collaborative effort to enhance healthcare services.

Project Overview

The consortium comprises:

• - AMI Corporation
• - Gunma University
• - Gunma Central Hospital

The primary theme of this project is the "Early Detection of Heart Failure Using Cardiac Sound Graph Tests". Through joint research, AMI Corporation and Gunma University will integrate AI into the "super stethoscope" technology. This advancement will facilitate remote diagnostic assistance, aiming to detect heart failure at an early stage and ultimately enhance the health and lifespan of the residents in Gunma Prefecture through digital technology.

Project Timeline

The project is set to commence from the date of funding approval and conclude on February 27, 2024.

About the Gunma Future Co-creation Trial Subsidy

The Gunma Prefecture government implements this subsidy program to support new business implementation and social proof projects that utilize digital technologies to bring innovation into the local industrial society. The areas covered include VIRTUAL/AI, Transportation & Logistics, Healthcare, AgriTech & FoodTech, Disaster Prevention & Resilience, Infrastructure Maintenance, and GreenTech. The goal is to stimulate groundbreaking advancements in these sectors, specifically in healthcare innovations.

Consortium Partners

• - Gunma University: Visit Website
• - Gunma Central Hospital: Visit Website
• - AMI Corporation: A startup known for developing the super stethoscope with remote medical capabilities, focusing on "Stethoscope DX". Their aim is to enable high-quality medical care accessible to everyone, regardless of location, leveraging acoustic engineering, electronics, and AI technology.

Their mission is not only to digitalize auscultation but also to create new value in clinical research and medical education through remote healthcare applications, thereby enhancing the overall quality of medical services provided.

Additional Resources

For a deeper insight into AMI's mission and capabilities, watch their promotional video here.

Company Overview

• - Company Name: AMI Corporation
• - CEO: Shimpei Ogawa
• - Founded: November 2015
• - Website: ami.inc
• - Head Office: 2-13 Higashi-senju, Kagoshima City, Kagoshima Prefecture
• - Branch Office: 5-98 Hamamatsu Town, Minamata City, Kumamoto Prefecture
• - Business Focus: Development of medical devices and provision of telemedicine services.

This announcement serves to inform stakeholders, including media, shareholders, and investors, about AMI's ongoing initiatives and is not intended for general public medical information dissemination.